Plethora Solutions Holdings Plc Regulatory News (PLE)

18 September 2014

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

Result of General Meeting and update regarding the Fundraising to raise £18.2 million in aggregate

Plethora Solutions Holdings plc (AIM: PLE) is pleased to announce that further to the announcements by the Company on 29 August and 2 September 2014 (the "Announcements") in relation to the Placing and Subscription to raise £15.9 million gross and the further subscription of £2.3 million from Regent Pacific Group Limited (together the "Fundraise") all resolutions, as set out in the Notice of General Meeting sent to Shareholders on 1 September 2014 in connection with the Fundraise, were duly passed at the Company's general meeting of shareholders held today.

The Company is also pleased to announce that, as a result, the passing of the resolutions today and the announcement by the Company on 16 September 2014 in respect of the European licencing agreement entered into with Recordati (the "License Agreement"), application has been made for 202,297,976 new ordinary shares of 1 pence each in capital of the Company ("Ordinary Shares") to be admitted to trading on the AIM Market of the London Stock Exchange at 8:00 am on 19 September 2014 ("Admission"). The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue.

Following Admission, the Company will grant a total 101,148,981 warrants to subscribe for Ordinary Shares, with each warrant giving the holder the right, but not the obligation, to acquire one Ordinary Share at an exercise price of 15 pence at any time prior to the earlier of 19 September 2019 and 30 days after the date on which the Company gives the warrant holder notice of a change of control.

The 202,297,976 new Ordinary Shares and the 101,148,981 warrants are being issued in connection with the Placing and Subscription and the Regent Pacific Subscription, each as defined in the Announcements.

Following Admission, Plethora will use the net proceeds of the Placing and Subscription and the Regent Pacific Subscription to make the payments due in respect of the Cessation Agreements and the Patent Transfer Agreement, at which point the License Agreement shall become effective as described in the Company's announcement of 16 September 2014.

This announcement should be read in conjunction with the full text of the Announcements. Unless stated otherwise, capitalised terms in this announcement have the same meaning as given in the Announcements.

Following Admission, the Company's enlarged issued share capital will comprise 632,205,154 Ordinary Shares with one voting right per Ordinary Share. The Company does not hold any Ordinary Shares in Treasury. The total number of voting rights in the Company will therefore be 632,205,154. The total of 632,205,154 Ordinary Shares may therefore be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

About Plethora:

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk

Plethora is focussed on seeking to launch PSD502™ for the treatment of premature ejaculation.

About PSD502™ & Premature Ejaculation:

PSD502™ is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. In two large, double blind, pivotal Phase III studies PSD502™ showed a highly significant and clinically meaningful effect increasing mean intravaginal ejaculatory latency time at baseline from 0.5 minutes to 3.2 minutes at week 12. 87% of the patients in the studies were considered as responders with the product being well tolerated with no significant safety issues. PSD502™ also showed positive effects across a wide range of other parameters including partner satisfaction. PSD502™ was approved by the European Commission in November 2013.

Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20% to 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

The premature ejaculation market offers significant potential for development and growth given the absence of any widely approved pharmaceutical therapy with good patient acceptance. As a result an effective drug therapy for premature ejaculation may have a commercial potential comparable to erectile dysfunction drugs.